STOCK TITAN
  1. Home
  2. News
  3. PRTC

PureTech Health Plc - PRTC STOCK NEWS

Welcome to our dedicated news page for PureTech Health Plc (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on PureTech Health Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PureTech Health Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PureTech Health Plc's position in the market.

News
PureTech Health: Notice of Results
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announces plans to release its Annual Report and Accounts and financial results for the year ended December 31, 2023, on April 25, 2024. A presentation and conference call will follow to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Rhea-AI Summary
PureTech completes enrollment in Phase 2b ELEVATE IPF trial of LYT-100 for IPF, with topline results expected in Q4 2024. LYT-100 aims to address tolerability issues of current IPF treatments, showing promising results in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
Rhea-AI Summary
PureTech Health plc receives Fast Track designation from the FDA for LYT-200 in combination with anti-PD1 therapy for head and neck cancers, aiming to improve treatment outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
clinical trial
News
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
Rhea-AI Summary
PureTech Health plc announces key progress on strategic initiatives with Seaport Therapeutics raising $100 million in Series A financing. Bharatt Chowrira named CEO, Eric Elenko promoted to President, Daphne Zohar transitions to Seaport CEO, and Steven M. Paul as Chairman.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
management
-
News
PureTech Proposes $100 Million Capital Return
Rhea-AI Summary
PureTech Health plc announces a proposed capital return of $100 million to shareholders through a Tender Offer at 250 pence per Ordinary Share Premium of 25%. This follows the completion of Karuna Therapeutics' $14 billion acquisition by Bristol Myers Squibb. The Tender Offer, subject to shareholder approval, will be launched after the Company's Full Year Results in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
none
-
News
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Rhea-AI Summary
PureTech Health plc announces the completed acquisition of Karuna Therapeutics, Inc. by Bristol Myers Squibb for approximately $14 billion. PureTech to receive $293 million gross proceeds from its equity position in Karuna. KarXT, a potential first-in-class treatment for schizophrenia, has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. Bristol Myers Squibb expects the transaction to be dilutive to its non-GAAP diluted earnings per share by approximately $0.30 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
acquisition
News
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
Rhea-AI Summary
PureTech Health plc receives orphan drug designation from the FDA for LYT-200 in the treatment of acute myeloid leukemia (AML), showcasing potential for a novel and effective therapy. The FDA recognition validates the innovative approach of targeting galectin-9 with LYT-200, offering hope for patients with relapsed or refractory AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
clinical trial
-
News
PureTech to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
PureTech Health plc (PRTC) announces participation in upcoming investor conferences, showcasing key management team members and presenting webcasts for investor access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
conferences
-
News
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Rhea-AI Summary
PureTech Health's Japanese partner, Shionogi & Co. Ltd, submits Akili's digital therapeutic SDT-001 for marketing approval in Japan, a localized version of AKL-T01. The Phase 3 clinical trial results show significant improvements in pediatric ADHD patients. Positive outcomes pave the way for potential nationwide marketing approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
clinical trial
News
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PureTech Health plc (PRTC) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock PRTC logo
PureTech Health Plc

Nasdaq:PRTC

PRTC Rankings

#2654 Ranked by Market Cap
#3907 Ranked by Stock Gains
N/A Ranked by Dividends

PRTC Stock Data

734.36M
154.84M
0.04%
0.02%
Investment Advice
Finance and Insurance
Link
US
Boston

About PRTC

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.